Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2007-03-19 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report used to announce major events that shareholders should know about. The text specifically mentions "Entry Into a Material Definitive Agreement" and references an amendment to a license agreement. It also states that the amendment will be filed as an exhibit to the Annual Report on Form 10-K, indicating this document is not the annual report itself but a current event disclosure. The document length is 2480 characters, which is relatively short and consistent with an 8-K filing. There is no detailed financial data or comprehensive report content, so it does not qualify as an Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements like Form 8-K filings that do not fit other categories.
2007-03-19 English
Proxy Solicitation & Information Statement 2007
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed pursuant to Rule 14a-101 under the Securities Exchange Act of 1934. It is titled as a Proxy Statement for the 2007 Annual Meeting of Shareholders of Targeted Genetics Corporation. The content includes details about the annual meeting, proposals to be voted on by shareholders, voting instructions, and other related information. It is not a report of financial results, audit, or earnings release, but rather materials sent to shareholders to provide information and request votes for the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed proxy information, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2007-03-16 English
Remuneration Information 2007
Remuneration Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the Compensation Committee setting performance goals and bonus structures for executive officers for fiscal year 2007. This relates to executive compensation arrangements rather than a full annual report, earnings release, or other financial report. The document is relatively short (3416 characters) and contains specific information about compensatory arrangements of executive officers. This fits the category of Remuneration Information, which covers reports detailing compensation for top executives and directors. Therefore, the appropriate classification is DEF 14A (Remuneration Information).
2007-03-08 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes an announcement of a presentation of updated Phase I data at a conference and references a press release attached as an exhibit. The document is relatively short (2679 characters) and primarily serves as an announcement of an event and a press release, not a detailed financial report or earnings release. There is no substantive financial data or detailed management discussion. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2007-03-01 English
Capital/Financing Update 2007
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933, registering shares of common stock for resale by selling shareholders. It details the number of shares, the selling shareholders, the use of proceeds, risk factors, and company background. It is a disclosure document related to a securities offering, specifically a resale registration statement. This type of document is a capital markets filing related to financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the offering and related risks, consistent with a financing update.
2007-02-09 English
Regulatory Filings 2007
Regulatory Filings
2007-02-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.